{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:27:14Z","timestamp":1740126434000,"version":"3.37.3"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,21]]},"abstract":"<jats:p>The management of patients with paradoxical hidradenitis suppurativa receiving biologic therapy should be individualized, but the treatment of these reactions is mainly based on the discontinuation of the culprit drug taking into account the balance between subsequent risks and benefits.<\/jats:p>","DOI":"10.1093\/ced\/llad160","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T19:04:09Z","timestamp":1682449449000},"page":"940-941","source":"Crossref","is-referenced-by-count":0,"title":["Reply to \u2018Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on \u201cParadoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab\u201d\u2019"],"prefix":"10.1093","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6099-3241","authenticated-orcid":false,"given":"Pablo","family":"L\u00f3pez Sanz","sequence":"first","affiliation":[{"name":"Departments of Dermatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Guzm\u00e1n P\u00e9rez","sequence":"additional","affiliation":[{"name":"Internal Medicine, University General Hospital of Albacete , Albacete , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Guerrero Ram\u00edrez","sequence":"additional","affiliation":[{"name":"Departments of Dermatology and Internal Medicine, University General Hospital of Albacete , Albacete , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Manso C\u00f3rdoba","sequence":"additional","affiliation":[{"name":"Departments of Dermatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Encarnaci\u00f3n","family":"Alfaro Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Departments of Dermatology and Internal Medicine, University General Hospital of Albacete , Albacete , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Manuel","family":"Aza\u00f1a Defez","sequence":"additional","affiliation":[{"name":"Departments of Dermatology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"key":"2023101015420820400_llad160-B1","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/ced\/llad082","article-title":"Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on \u2018Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab\u2019","volume":"48","author":"Martora","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"2023101015420820400_llad160-B2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/ced\/llad003","article-title":"Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab","volume":"48","author":"L\u00f3pez Sanz","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"2023101015420820400_llad160-B3","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3390\/biomedicines10020455","article-title":"Paradoxical hidradenitis suppurativa during biologic therapy, an emerging challenge: a systematic review","volume":"10","author":"Ruggiero","year":"2022","journal-title":"Biomedicines"},{"key":"2023101015420820400_llad160-B4","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.jaad.2016.01.018","article-title":"Hidradenitis suppurativa (HS): an unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases","volume":"74","author":"Faivre","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2023101015420820400_llad160-B5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000503605","article-title":"A comparison of international management guidelines for hidradenitis suppurativa","volume":"237","author":"Hendricks","year":"2021","journal-title":"Dermatology"},{"key":"2023101015420820400_llad160-B6","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/bjd\/ljad010","article-title":"Guselkumab for hidradenitis suppurativa: a phase II, open label, mode of action study","volume":"88","author":"Dudink","year":"2023","journal-title":"Br J Dermatol"},{"key":"2023101015420820400_llad160-B7","doi-asserted-by":"crossref","first-page":"155585","DOI":"10.1016\/j.cyto.2021.155585","article-title":"Serum high-sensitivity C-reactive protein, tumor necrosis factor-\u03b1, interleukin (IL)-1\u03b2, IL-17A and IL-23 levels in patients with hidradenitis suppurativa","volume":"144","author":"Sara\u00e7 \u00d6zt\u00fcrk","year":"2021","journal-title":"Cytokine"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llad160\/50514524\/llad160.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/8\/940\/51990368\/llad160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/8\/940\/51990368\/llad160.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T15:43:05Z","timestamp":1696952585000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/48\/8\/940\/7142641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":7,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,4,25]]},"published-print":{"date-parts":[[2023,7,21]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llad160","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"type":"print","value":"0307-6938"},{"type":"electronic","value":"1365-2230"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2023,4,25]]}}}